5Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non- amscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results [ J 3. Eur Uro1,2008,53 ( 1 ) :45-52.
6Ojea A, Nogueira JL, Solsona E, et al. A muhicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette- Guerin ( 13.5 rag) versus mitomycin C [ J]. Eur Urol, 2007,52 (5) :1398-1406.
7Lamm DL, Blumenstein BA, David Crawford E, et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder [ J ]. Urol Oncol, 1995,1 (3) : 119-126.
8Krege S, Giani G, Meyer R, et al. A randomized muhicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transuretbral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin [ J ]. J Urol, 1996,156 ( 3 ) : 962 -966.
9Witjes JA, Meijden AP,Collette L,et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer[ J]. Urology,1998,52(3) :403-410.
10Snfits G, Schaafsma E, Kiemeney L, et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. [Jl. Urology,1998,52(6) :1009-1014.
